A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women

Inclusion Criteria: * Female gender * ≥ 50 years of age * DXA T-score of \> -2.5 standard deviations, but ≤ -1 (osteopenic range) * Steady state body weight 1 month before study commencement date * No contraindications for intake of the interventional product, including a prior diagnosis of fish allergy. * Familiar with the Norwegian language, both in writing and orally Exclusion Criteria: * A diagnosis of osteoporosis (BMD T-score ≤ -2.5 SD as diagnosed by DXA), or any previously diagnosed fragility fractures on a background of osteoporosis. * Use of drugs known to affect bone metabolism, including: * Glucocorticoids * Thyroid hormones * Hormone replacement therapy taken continuously for a duration of less than 6 months. * Long-term heparin therapy * Anti-convulsive drugs * Long-term proton pump inhibitor treatment * Lithium * Anti-osteoporotic drugs * Cancer therapy * Selective estrogen receptor modulators. * Any disease or medical condition known to affect bone tissue, including neoplasia with or without metastasis, Paget's disease of bone, Osteomalacia, or any other disease deemed relevant by the PI. * Gastrointestinal diseases or disturbances potentially affecting absorption of nutrients, including Crohn's disease and Celiac disease. * Hypersensitivity to ingredients in the interventional product, including fish allergy. * Not willing to participate in the study. * Other reasons that the PI deems it necessary to exclude the subject.